TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05245552

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine(0.25ml)
Description: 7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine(0.25ml)
Description: 7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine(0.5ml)
Description: 15 ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine(BV)
Description: 7.5μg inactivated influenza antigen (H1N1, H3N2, Victoria) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine(BY)
Description: 7.5μg inactivated influenza antigen (H1N1, H3N2, and Yamagata) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
Study: NCT06359925

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprazygomatic maxillary nerve block using dexmedetomidne and Bupivacaine
Description: After induction of general anaesthesia blockade of the contents of the pterygopalatine fossa is performed bilaterally before starting surgery as follows: After complete aseptic skin preparation and under ultrasound guidance images are obtained with a high-frequency linear array probe. The ultrasound transducer is placed in the infrazygomatic area, over the maxilla, angled \[45 \]degree cephalad. This probe position allows visualization of the pterygopalatine fossa,The needle is advanced using an out-of-plane approach, and the needle tip can usually be identified during movements. the injectate consisted of \[4\]mL of \[0.5% \]Bupivacaine combined with \[1\]mL of\[ 5\]µg dexmedetomidine. The injectate is delivered over \[15-20 \] seconds, while observing the spread of the local anesthetic under ultrasoundThe same procedure is then repeated on the contralateral side.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Suprazygomatic maxillary nerve block using Bupivacaine
Description: After induction of general anaesthesia blockade of the contents of the pterygopalatine fossa is performed bilaterally before starting surgery as follows: After complete aseptic skin preparation and under ultrasound guidance images are obtained with a high-frequency linear array probe. The ultrasound transducer is placed in the infrazygomatic area, over the maxilla, angled \[45 \]degree cephalad. This probe position allows visualization of the pterygopalatine fossa,The needle is advanced using an out-of-plane approach, and the needle tip can usually be identified during movements. the injectate consisted of \[4\]mL of \[0.5% \]Bupivacaine combined with \[1\]mL normal saline . The injectate is delivered over \[15-20 \] seconds, while observing the spread of the local anesthetic under ultrasoundThe same procedure is then repeated on the contralateral side.
Study: NCT04683068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message comparison
Description: Message comparison

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Message comparison
Description: Message comparison
Study: NCT06316453

Intervention type: OTHER
Intervention: Evaluating ASCVD risk over 10 and 30 year and lifetime
Description: Utilizing validated tools such as the Pooled Cohort Equations (PCE) for 10-year ASCVD risk, the 30-year ASCVD risk prediction tool, and lifetime ASCVD risk categories, participants will undergo a thorough risk assessment. This multi-dimensional approach ensures a nuanced understanding of short and long-term cardiovascular risks. Further, The genetic risk for ApoB will be meticulously assessed by genotyping the APOB rs1042031 variant. Subsequently, the calculation of the genetic risk score (GRS) based on risk alleles will provide personalized insight into genetic predispositions related to ASCVD risk. Moreover, Participants will receive personalized management recommendations derived from the ACC/AHA Cardiovascular Risk Assessment Guidelines. These tailored suggestions may encompass dietary programs, lifestyle modifications, and, when indicated, pharmaceutical therapies like statins, aiming to mitigate identified risks effectively
Study: NCT06126003

Intervention type: OTHER
Intervention: Observation
Description: No Intervention
Study: NCT04578938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Description: Single subanesthetic infusion of ketamine (0.5mg/kg)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intravenous ketamine
Description: Single subanesthetic infusion of ketamine (0.5mg/kg)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: 8 sessions of computer-based cognitive training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: 8 sessions of computer-based cognitive training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: 8 sessions of computer-based sham training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: 8 sessions of computer-based sham training
Study: NCT06406504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: in-laboratory simulation group
Description: The students in-laboratory group performed the simulation applications in the patient room in the simulation laboratory. One of the Stage 2 and one of the Stage 3 PI was created by the researcher with moulage to the heel and lateral malleolus area of the standardised patient taken to the patient room.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: in-situ simulation group
Description: Students in the in-situ simulation group performed the simulation practices in a patient room in a clinic at a university hospital. One of the Stage 2 and one of the Stage 3 PI was created by the researcher with moulage to the heel and lateral malleolus area of the standardised patient taken to the patient room.
Study: NCT05541705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Oscillation Walking
Description: Each participant with stroke will partake in 18 training sessions. Training sessions will be for one hour three times a week for 6 weeks. During training, participants will walk at their self-selected walking speed on the treadmill that moves side-to-side for 1 cm in a sinusoidal pattern. The sinusoidal oscillation frequency will match each participant's natural stride frequency calculated from baseline evaluation. Subjects will be instructed to respond naturally and maintain continuous walking. Participants will wear a safety harness with no body weight support. For each training session, six 6-minute bouts of treadmill oscillation trials will be performed (Hsiao et al. 2016) and rest period will be provided between bouts. Because lower extremity muscle activity increases with increasing oscillation frequency, the treadmill oscillation frequency will be increased by 5% each week to continue to drive progressive adaptive changes (25% over 6 weeks) (Pohl et al. 2002).
Study: NCT05322993

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GI Genius
Description: The use of artificial intelligence during colonoscopy to improve polyp detection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard white light colonoscope
Description: Standard colonoscopy.
Study: NCT05402696

Intervention type: PROCEDURE
Intervention: Endoscopic tissue resection
Description: Endoscopic resection techniques for removal of large polyps
Study: NCT06363071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight shift training and APA feedback
Description: Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation
Description: Use TMS combine ES to stimulate TA nerve and M1 cortical

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation
Description: Use TMS combine ES to stimulate TA nerve and M1 cortical

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation
Description: Use TMS combine ES to stimulate TA nerve and M1 cortical
Study: NCT05568238

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vacuum Assisted Wound Closure and Permanent On-lay Mesh-mediated fascial traction (VAWCPOM)
Description: Vacuum Assisted Wound Closure and Permanent On-lay Mesh-mediated fascial traction (VAWCPOM) in patients with open abdomen.
Study: NCT05715918

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine for intramuscular injection
Description: Volunteers ( Group 1 - 150) will receive the vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator (without active ingredient) for intramuscular injection
Description: Volunteers ( Group 2 - 150) will receive the vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
Study: NCT05339217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telitacicept
Description: 160mg Telitacicept was subcutaneously injected to patients with systemic lupus erythematosus at the outer side of upper arm every week for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: 160mg Telitacicept was subcutaneously injected to patients with systemic lupus erythematosus at the outer side of upper arm every week for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Description: Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
Study: NCT05581056

Intervention type: DRUG
Intervention: CFTR modulators
Description: Introduction of CFTR modulators by pneumologists for pneumologic issues
Study: NCT06460584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pursed Lip Breathing
Description: In each set, 10 times will be included. Reading will be taken from 1st POD and comparison will be done on each 4rth POD. Ask the patient to sit in a comfortable position and relax. Then, instruct the patient to take deep breath 12 through nose for two counts, and keep mouth closed. Inhale for 2 seconds. Now, ask the patient to purse the lips as if the patient was going to gently flicker the flame of candle. Now the patient will breathe out gently while counting for 4 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incentive Spirometer
Description: For the use of flow based IS, the Patient will be sited in a comfortable Position (Semi-Recumbent Position Of 45 Degrees), With a Pillow under the knees or Semi-Fowler Position on bed, and then asked to perform this technique with the same order to ensure that she / he understands the process. The patient will be instructed to inhale with a slow continuous and deep breathing, and hold for a period of not less than 5 seconds and exhale passively. And is instructed to hold the spirometry upright to perform slowly inhalation, thus lifting the ball. At the end of the evaluation of respiratory measures for patients with lung function, and then compare the results with the previous results. IS will be recommended to be performed by patient every 10 breaths hourly and 5 times per day.
Study: NCT06226675

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG Block
Description: To apply local anesthetic under psoas tendon

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG Block
Description: To apply local anesthetic under psoas tendon

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LFCN block
Description: to apply local anesthetic around lateral femoral cutaneous nerve
Study: NCT05880004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Application for Food PAntrieS (SAFPAS) - A mobile app that helps food pantries recruit, train and schedule volunteers, offer choice safely, and provides multilevel communications
Description: The primary intervention is a mobile application (app) which supports food pantries to recruit, train and schedule volunteers; provide a safe, remote form of client choice; and provides a means of sharing real-time status information with clients, pantries, food banks, and emergency operation centers. Following formative work, user centered design, and usability testing, the SAFPAS app will be implemented in three stages, where each stage introduces new features. Pantry clients will be encouraged to download the app and learn its key features at the end of baseline data collection. During the first weeks of each stage, training of participating food pantry directors/staff and Maryland Food Bank (MFB) staff will take place - focusing on use of any new features. Initial training will be follow up by proficiency testing.
Study: NCT04958239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765179
Description: BI 765179
Study: NCT04932356

Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic education by phone
Description: The patients who participate in the intervention group, after their face-to-face visit, will undergo a fortnightly reinforcement by telephone of diabetes education (review of diet, physical exercise, doubts about insulin or oral medication and the registry of blood glucose controls). In addition, emotional support will be provided to the patient, along with a semester calendar with scheduled calls to carry out the intervention, at a specific time.

Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutical education traditional
Description: The patients participating in the study will be visited in person every six months where the control group will follow the usual protocol of the health center in the face-to-face visits, with their respective analyzes and pertinent tests, together with health education and adherence to pharmacological treatment.
Study: NCT04958239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765179
Description: BI 765179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765179
Description: BI 765179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765179
Description: BI 765179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab
Study: NCT05920460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Program
Description: Brief description of the Cognitive Behavioral Therapy program is given below:~* Session 1: Mutual understanding and rapprochement~* Session 2: Sleep hygiene education~* Session 3: Psychoeducation about stimulus control strategies; monitoring sleep environments, and identification of behavioral habits at bedtime, dysfunctional beliefs, and attitudes about sleep.~* Session 4: Training on relaxation techniques~* Session 5: Psycho education about depression~* Session 6: Cognitive restructuring~* Session 7: The terminating session
Study: NCT04772859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Lifestyle Intervention
Description: The intervention will be based on the Planet Nutrition program. This program was previously designed by the present research group and has a handbook that includes nutrition topics, framed by different behavior change strategies. The nutrition education and physical activity sessions will be offered 3 days a week, in the same 1-hour class: 30 minutes for each.~Nutrition education: presentations based on the Planet Nutrition program, a dedicated website, and the Zoom application, will be used to deliver the intervention. The website will be used to upload the nutrition materials and the recorded sessions. Participants will work on self-monitoring of different health behaviors.~Physical activity: The classes will be delivered by the Physical Activity team through the Zoom application. A website will be used to upload the recorded sessions.~Parents participation. The same website and a private Facebook group will be used to upload nutrition information once a week.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: They will receive one digital brochure with general information on a healthy diet, at the beginning of the program.
Study: NCT04547868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of coffee will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decaffeinated Coffee
Description: Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of decaffeinated coffee will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Warm water
Description: Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of warm water will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.
Study: NCT06233344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin plus mindfulness training
Description: Participants will receive a single 25 mg dose of psilocybin under the supervision of study therapists. The psilocybin dosing session will take place approximately halfway through an 8-week mindfulness training course. The mindfulness training course will consist of weekly 2-hour classes with experienced mindfulness teachers; participants will be encouraged to practice mindfulness for 45 minutes per day between classes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: Participants will receive a single 25 mg dose of psilocybin under the supervision of study therapists.
Study: NCT04787302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-231
Description: Cohort 1: 30mg dose of CVL-231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-231
Description: Cohort 2: CVL-231 dose to be decided based on results of Cohort 1 or trial may be concluded

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-231
Description: Cohort 3: CVL-231 dose to be decided based on results of Cohorts 1 and/or 2
Study: NCT05424926

Intervention type: OTHER
Intervention: collection of clinical parameters and blood sample
Description: * A baseline visit, with collection of clinical parameters and blood sample to measure anti-infliximab antibodies and infliximab trough levels.~* Follow-up visits at 3 months (in outpatient clinic for clinical evaluation), 6 months and 12 months (in day hospitalization for clinical evaluation and blood sample collection for ADA detection and infliximab trough level measurement).